16. The vector of claim 1 or 5, wherein the promoter is a CMV promoter, a RSV promoter, a SV40 promoter, a HSV promoter, a human Pol I promoter, a human Pol II promoter, or a human Pol III promoter.

17. A composition comprising the vector of claim 1 or 5 and a carrier.

18. A pharmaceutical composition comprising the vector of claim 14 or 15 and a pharmaceutically acceptable carrier.

19. A vaccine comprising a therapeutically effective amount of a vector of claim 14 or 15.

20. A vaccine comprising a therapeutically effective amount of the pharmaceutical composition of claim 18.

21. A homogenous population of clonally purified (+) SS RNA virus obtained from eukaryotic cells transfected with the vector of claim 1 or 5.

22. A composition comprising the homogeneous population of clonally purified (+) SS RNA virus of claim 21 and a carrier.

23. A pharmaceutical composition comprising the homogenous population of clonally purified (+)SS RNA virus of claim 21 and a pharmaceutically acceptable carrier.

24. A vaccine comprising a therapeutically effective amount of a homogeneous clonally purified live (+)SS RNA virus population obtained from cells transfected with the vector of claim 14 or 15.

25. A method of preparing a homogeneous clonally purified live (+)SS RNA virus population, wherein the method comprises transfecting the vector of claim 1 or 5 into a eukaryotic cell and isolating (+)SS RNA viruses, thereby obtaining the homogeneous clonally purified live (+)SS RNA virus population.

26. The method of claim 25, wherein the eukaryotic cell is a Vero cell, a CHO cell, or a MDCK cell.

27. A method of preparing a vaccine for protecting a subject against a disease caused by an infectious (+) SS RNA virus, wherein the method comprises transfecting the vector of claim 14 or 15 into a eukaryotic cell and isolating the (+) SS RNA viruses, thereby obtaining a vaccine.

28. The method of claim 27, wherein the eukaryotic cell is a Vero cell, a CHO cell, or a MDCK cell.

29. Use of the vector of claim 1 or 5 in the manufacture of a vaccine for protecting a subject against a disease caused by an infectious (+) SS RNA virus.

30. The use of claim 29, wherein the subject is a mammal.

31. The use of claim 30, wherein the mammal is a human or a veterinary animal.

32. A method of preparing a stable plasmid, wherein the method comprises a DNA encoding a genomic RNA of an infectious (+) SS RNA virus, wherein the method comprises introducing at least three introns into the DNA, and wherein at least one intron is in the region encoding a structural protein of the (+) SS RNA virus and at least one intron is in the region encoding a nonstructural protein of the (+) SS RNA virus.

33. A method of preparing a vector of claim 1 or 5, wherein the method comprises transfecting the vector of claim 1 or 5 into a host cell and isolating the vector from the host cell.

34. An isolated cell transfected with a vector of claim 1 or 5.

35. Use of the vector of claim 1 or 5 in the manufacture of a vaccine for protecting a subject against a disease caused by an infectious (+) SS RNA virus, wherein the vaccine comprises the homogeneous clonally purified live (+)SS RNA virus population of claim 25.